» Articles » PMID: 26647773

Growth Differentiation Factor 15 May Protect the Myocardium from No‑reflow by Inhibiting the Inflammatory‑like Response That Predominantly Involves Neutrophil Infiltration

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2015 Dec 10
PMID 26647773
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the current study was to investigate the time course of the expression of growth differentiation factor‑15 (GDF‑15) in rat ischemic myocardium with increasing durations of reperfusion, and to elucidate its physiopathological role in the no‑reflow phenomenon. Wistar rats were randomly divided into ischemia reperfusion (I/R) and sham groups, and myocardial I/R was established by ligation of the left anterior descending coronary artery for 1 h followed by reperfusion for 2, 4, 6, 12, 24 h and 7 days whilst rats in the sham group were subjected to a sham operation. The expression levels of GDF‑15 and ICAM‑1 were measured, in addition to myeloperoxidase (MPO) activity. The myocardial anatomical no‑reflow and infarction areas were assessed. The area at risk was not significantly different following various periods of reperfusion, while the infarct area and no‑reflow area were significantly greater following 6 h of reperfusion (P<0.05). The mRNA and protein expression levels of GDF‑15 were increased during the onset and development of no‑reflow, and peaked following 24 h of reperfusion. MPO activity was reduced with increasing reperfusion duration, while ICAM‑1 levels were increased. Hematoxylin and eosin staining demonstrated that myocardial neutrophil infiltration was significantly increased by I/R injury, in particular following 2, 4 and 6 h of reperfusion. GDF‑15 expression levels were negatively correlated with MPO activity (r=‑0.55, P<0.001), and the MPO activity was negatively correlated with the area of no‑reflow (r=‑0.46, P<0.01). By contrast, GDF‑15 was significantly positively correlated with ICAM‑1 levels (r=0.52, P<0.01), which additionally were demonstrated to be significantly positively associated with the size of the no‑reflow area (r=0.39, P<0.05). The current study demonstrated the time course effect of reperfusion on the expression of GDF‑15 in the myocardial I/R rat model, with the shorter reperfusion times (6 h) resulting in significant no‑reflow in ischemic myocardium. GDF‑15 may protect the I/R myocardium from no‑reflow by inhibiting the inflammatory‑like response, which involves neutrophil infiltration and transendothelial migration.

Citing Articles

GDF15/MIC-1: a stress-induced immunosuppressive factor which promotes the aging process.

Salminen A Biogerontology. 2024; 26(1):19.

PMID: 39643709 PMC: 11624233. DOI: 10.1007/s10522-024-10164-0.


Growth/differentiation factor 15 (GDF15) expression in the heart after myocardial infarction and cardioprotective effect of pre-ischemic rGDF15 administration.

Dogon G, Rigal E, Potel E, Josse M, Rochette L, Bejot Y Sci Rep. 2024; 14(1):12949.

PMID: 38839839 PMC: 11153639. DOI: 10.1038/s41598-024-63880-5.


Growth differentiation factor-15 as a negative predictor for microvascular obstruction in ST-segment elevation myocardial infarction after primary percutaneous coronary intervention.

Wu X, Bai J, Tan Y, Wei Z, Dai Q, Kang L Int J Cardiovasc Imaging. 2024; 40(4):863-871.

PMID: 38430425 DOI: 10.1007/s10554-024-03055-5.


GDF15 restrains myocardial ischemia-reperfusion injury through inhibiting GPX4 mediated ferroptosis.

Gao Q, Li C, Zhong P, Yu Y, Luo Z, Chen H Aging (Albany NY). 2024; 16(1):617-626.

PMID: 38206295 PMC: 10817394. DOI: 10.18632/aging.205402.


A historical literature review of coronary microvascular obstruction and intra-myocardial hemorrhage as functional/structural phenomena.

Maslov L, Naryzhnaya N, Popov S, Mukhomedzyanov A, Derkachev I, Kurbatov B J Biomed Res. 2023; 37(4):281-302.

PMID: 37503711 PMC: 10387746. DOI: 10.7555/JBR.37.20230021.


References
1.
Wollert K . Growth-differentiation factor-15 in cardiovascular disease: from bench to bedside, and back. Basic Res Cardiol. 2007; 102(5):412-5. DOI: 10.1007/s00395-007-0662-3. View

2.
Reffelmann T, Kloner R . The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol. 2006; 101(5):359-72. DOI: 10.1007/s00395-006-0615-2. View

3.
Nallamothu B, Bradley E, Krumholz H . Time to treatment in primary percutaneous coronary intervention. N Engl J Med. 2007; 357(16):1631-8. DOI: 10.1056/NEJMra065985. View

4.
Kempf T, Bjorklund E, Olofsson S, Lindahl B, Allhoff T, Peter T . Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007; 28(23):2858-65. DOI: 10.1093/eurheartj/ehm465. View

5.
Lin J, Hung L, Lai L, Wei F . Kappa-opioid receptor agonist protects the microcirculation of skeletal muscle from ischemia reperfusion injury. Ann Plast Surg. 2008; 61(3):330-6. DOI: 10.1097/SAP.0b013e31815b9e64. View